Advances in Local and Systemic Therapies for Hepatocellular Cancer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the past two decades. Although transplantation and surgical resection offer a chance for cure and long-term survival, most patients present with more advanced tumor stage when these therapies are not possible. Although rarely curative, locoregional therapy with transarterial chemoembolization or radioembolization offers a survival benefit for those with liver-isolated HCC who are not amenable to curative therapies. Patients with metastatic disease or macrovascular invasion are treated with systemic therapy; however, median survival remains below 1 year. Patients with severe liver dysfunction or poor performance status should be treated with best supportive care given poor prognosis and no survival benefit for treatment. Lack of predictive and prognostic biomarkers in intermediate and advanced HCC tumors has hampered integration of clinical and molecular data to aid tailoring treatment decisions. However, with increasingly complex treatment decisions, optimal outcomes are achieved through multidisciplinary care.

Original languageEnglish (US)
Article number9
Pages (from-to)1-12
Number of pages12
JournalCurrent Oncology Reports
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Survival
Therapeutics
Liver Diseases
Neoplasms
Transplantation
Biomarkers
Mortality
Liver
Incidence

Keywords

  • Hepatocellular carcinoma
  • Liver cancer
  • Liver disease
  • Locoregional therapy
  • Staging
  • Systemic therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Advances in Local and Systemic Therapies for Hepatocellular Cancer. / Mokdad, Ali A.; Singal, Amit G.; Yopp, Adam C.

In: Current Oncology Reports, Vol. 18, No. 2, 9, 01.02.2016, p. 1-12.

Research output: Contribution to journalArticle

@article{336991ae1b6247e08993faeaf9b67c23,
title = "Advances in Local and Systemic Therapies for Hepatocellular Cancer",
abstract = "Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the past two decades. Although transplantation and surgical resection offer a chance for cure and long-term survival, most patients present with more advanced tumor stage when these therapies are not possible. Although rarely curative, locoregional therapy with transarterial chemoembolization or radioembolization offers a survival benefit for those with liver-isolated HCC who are not amenable to curative therapies. Patients with metastatic disease or macrovascular invasion are treated with systemic therapy; however, median survival remains below 1 year. Patients with severe liver dysfunction or poor performance status should be treated with best supportive care given poor prognosis and no survival benefit for treatment. Lack of predictive and prognostic biomarkers in intermediate and advanced HCC tumors has hampered integration of clinical and molecular data to aid tailoring treatment decisions. However, with increasingly complex treatment decisions, optimal outcomes are achieved through multidisciplinary care.",
keywords = "Hepatocellular carcinoma, Liver cancer, Liver disease, Locoregional therapy, Staging, Systemic therapy",
author = "Mokdad, {Ali A.} and Singal, {Amit G.} and Yopp, {Adam C.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11912-015-0494-5",
language = "English (US)",
volume = "18",
pages = "1--12",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Advances in Local and Systemic Therapies for Hepatocellular Cancer

AU - Mokdad, Ali A.

AU - Singal, Amit G.

AU - Yopp, Adam C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the past two decades. Although transplantation and surgical resection offer a chance for cure and long-term survival, most patients present with more advanced tumor stage when these therapies are not possible. Although rarely curative, locoregional therapy with transarterial chemoembolization or radioembolization offers a survival benefit for those with liver-isolated HCC who are not amenable to curative therapies. Patients with metastatic disease or macrovascular invasion are treated with systemic therapy; however, median survival remains below 1 year. Patients with severe liver dysfunction or poor performance status should be treated with best supportive care given poor prognosis and no survival benefit for treatment. Lack of predictive and prognostic biomarkers in intermediate and advanced HCC tumors has hampered integration of clinical and molecular data to aid tailoring treatment decisions. However, with increasingly complex treatment decisions, optimal outcomes are achieved through multidisciplinary care.

AB - Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the past two decades. Although transplantation and surgical resection offer a chance for cure and long-term survival, most patients present with more advanced tumor stage when these therapies are not possible. Although rarely curative, locoregional therapy with transarterial chemoembolization or radioembolization offers a survival benefit for those with liver-isolated HCC who are not amenable to curative therapies. Patients with metastatic disease or macrovascular invasion are treated with systemic therapy; however, median survival remains below 1 year. Patients with severe liver dysfunction or poor performance status should be treated with best supportive care given poor prognosis and no survival benefit for treatment. Lack of predictive and prognostic biomarkers in intermediate and advanced HCC tumors has hampered integration of clinical and molecular data to aid tailoring treatment decisions. However, with increasingly complex treatment decisions, optimal outcomes are achieved through multidisciplinary care.

KW - Hepatocellular carcinoma

KW - Liver cancer

KW - Liver disease

KW - Locoregional therapy

KW - Staging

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=84954433898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954433898&partnerID=8YFLogxK

U2 - 10.1007/s11912-015-0494-5

DO - 10.1007/s11912-015-0494-5

M3 - Article

C2 - 26769114

AN - SCOPUS:84954433898

VL - 18

SP - 1

EP - 12

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

M1 - 9

ER -